Influence of genetic polymorphisms in CYP3A4, CYP3AS, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma

Haematologica

Volumn 92, Issue 2, 2007, Pages 277-278

  Schilthuizen, Céline ^a   Broyl, Annemiek ^a   Van Der Holt, Bronno ^a   De Knegt, Yvonne ^a   Lokhorst, Henk ^b   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Gentic polymorphism; Multiple myeloma; Survival; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN 1; VINCA ALKALOID; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GSTP1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; GENETIC CODE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ADULT; AGED; FEMALE; GENETICS; LETTER; MALE; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 33947538297     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10618     Document Type: Article

References (6)

1. Harousseau JL, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev 2002;16:245-53.
2. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
3. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101:2144-51.
4. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998;34:1493-9.
5. Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003;102:2345-50.
6. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:567-71.